Ocugen (OCGN) vs Scribe Therapeutics (SCTX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 7, 2026.
Summary
Ocugen is the larger company by market cap ($339.1 million vs $332.6 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Head-to-head
| Metric | OCGN | SCTX |
|---|---|---|
| Share price | $1.00 | $17.57 |
| Market cap | $339.11M | $332.63M |
| 1-day change | -3.85% | +7.59% |
| EPS (TTM) | $-0.26 | $-3.84 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $2.73 | $39.60 |
| 52-week low | $0.97 | $13.50 |
| Distance from 52-week high | -63.30% | -55.63% |
| Average volume | 5.84M | 356.27K |
| Shares outstanding | 339.11M | 18.93M |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
OCGN vs SCTX FAQ
Which is bigger, Ocugen or Scribe Therapeutics?
Ocugen (OCGN) is larger, with a market capitalization of $339.11M compared with $332.63M for Scribe Therapeutics (SCTX).
Are Ocugen and Scribe Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.